Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 49 min ago
Peer-reviewedCC BY 4.0Frontiers in Endocrinology

Bone metastases identify a high-risk subgroup in metastatic neuroendocrine tumors with particular relevance in NETs of unknown primary

  • Annie Mathew1,2
  • Anna Kyewski1,2
  • Pia Hauptmeier1,2
  • David Kersting2,3
  • Benedikt M. Schaarschmidt2,4
  • Dagmar Fuhrer1,2
  • Harald Lahner1,2
4 affiliations
  1. 1Department of Endocrinology, Diabetes and Metabolism and Division of Laboratory Research, University Hospital Essen, Endocrine Tumor Center at WTZ/Comprehensive Cancer Center and ENETS Center of Excellence, University of Duisburg-Essen
  2. 2Center of Endocrine Medicine, University of Duisburg-Essen
  3. 3Department of Nuclear Medicine, West German Cancer Center, German Cancer Consortium (DKTK) and National Center for Tumor Diseases site, University Hospital Essen, University of Duisburg-Essen
  4. 4Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen
Open at sourcePDFDOICite

Abstract

Background: Bone metastases (BM) are an increasingly recognized manifestation of advanced neuroendocrine tumors (NETs), but their prevalence and association with survival in NETs of unknown primary (CUP NET) remain insufficiently characterized. We assessed the prevalence of BM and their association with overall survival (OS) in patients with metastatic pancreatic NETs (PanNETs), small intestinal NETs (siNETs), and CUP NETs.

Methods: We conducted a retrospective analysis of 642 patients with histologically confirmed metastatic well-differentiated NETs who were treated at the European Neuroendocrine Tumour Society (ENETS) Center Essen between 2009 and 2023 using somatostatin-receptor (SSTR)- based hybrid imaging with 68Ga-DOTATOC PET/CT. The patients included 171 with PanNETs, 305 with siNETs, and 166 with CUP NETs. The primary outcome was OS, defined as the time from date of initial NET diagnosis to death from any cause. Secondary outcomes included BM prevalence, entity-specific survival according to BM status, BM morphology and timing, and skeletal-related events.

Results: BM were detected in 238 patients (37.1%) and were most frequent in CUP NETs (42.8%), followed by PanNETs (36.3%) and siNETs (34.4%). Median OS in the overall cohort was 77 months (95% confidence interval [CI], 64–89) in patients with BM and 141 months (95% CI, 119–186) in metastatic patients without BM (log-rank p < 0.001). In CUP NETs, median OS was 30 months in patients with BM and 66 months in metastatic patients without BM (log-rank p = 0.021). In multivariable Cox regression adjusted for age, sex, tumor grade, functioning status, and tumor entity, BM remained associated with shorter OS (hazard ratio [HR], 1.45; 95% CI, 1.13–1.85; p = 0.0034). In an entity-stratified model BM remained associated with OS (HR, 1.43; 95% CI, 1.09–1.89; p = 0.011). In the CUP NET subgroup, the adjusted HR associated with BM was 1.83 (95% CI, 1.17–2.85; p = 0.008).

Conclusion: BM were common in patients with metastatic NETs and are particularly prevalent and clinically relevant in CUP NET.

Related

  1. The Enemy of My Enemy: Two Cases of De Novo Metastatic Small-Cell Neuroendocrine Prostate Cancer with BRCA2 Alterations and Brain Metastases.
    Mads Fallesen Kjer, Mads Hvid Poulsen, Sanne Kjær-Frifeldt +3
    International journal of molecular sciencesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Metastatic prostate cancer with neuroendocrine differentiation and liver metastases: prognosis and response to platinum-based chemotherapy.
    Christian W Schaaf, G von Amsberg, J J Werner +14
    World journal of urologyPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  3. Widespread Cutaneous Metastases as the Primary Presentation of an Occult Neuroendocrine Tumour of Unknown Primary
    Anesa Noor, Fatma Shah, Navdeep Sodhi +1
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Small Cell Neuroendocrine Carcinoma of the Bladder With Lymph Node Metastases: A Case Report
    Souad El Ourdi, Othmane Zouiten, Leila Afani +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Uncommon Tumor, Unusual Site, and Unconventional Behavior: Report of a Gastric Composite Gangliocytoma/Neuroma and Neuroendocrine Tumor (CoGNET) With Metastases
    Alicia Dessain, Vikas Prasad, Nikolaos Trikalinos +1
    International Journal of Surgical PathologyPeer-reviewedCC BY-NC 4.0Full textEpidemiology & public healthPMC

Cite

BibTeXRIS
BibTeX
@article{mathew2026bone,
  title = {{Bone metastases identify a high-risk subgroup in metastatic neuroendocrine tumors with particular relevance in NETs of unknown primary}},
  author = {Annie Mathew and Anna Kyewski and Pia Hauptmeier and David Kersting and Benedikt M. Schaarschmidt and Dagmar Fuhrer and Harald Lahner},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  month = oct,
  doi = {10.3389/fendo.2026.1906789},
  url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1906789/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Bone metastases identify a high-risk subgroup in metastatic neuroendocrine tumors with particular relevance in NETs of unknown primary
AU  - Annie Mathew
AU  - Anna Kyewski
AU  - Pia Hauptmeier
AU  - David Kersting
AU  - Benedikt M. Schaarschmidt
AU  - Dagmar Fuhrer
AU  - Harald Lahner
PY  - 2026
DA  - 2026/10/28
JO  - Frontiers in Endocrinology
DO  - 10.3389/fendo.2026.1906789
UR  - https://www.frontiersin.org/articles/10.3389/fendo.2026.1906789/full
AB  - Background: Bone metastases (BM) are an increasingly recognized manifestation of advanced neuroendocrine tumors (NETs), but their prevalence and association with survival in NETs of unknown primary (CUP NET) remain insufficiently characterized. We assessed the prevalence of BM and their association with overall survival (OS) in patients with metastatic pancreatic NETs (PanNETs), small intestinal NETs (siNETs), and CUP NETs.  Methods: We conducted a retrospective analysis of 642 patients with histologically confirmed metastatic well-differentiated NETs who were treated at the European Neuroendocrine Tumour Society (ENETS) Center Essen between 2009 and 2023 using somatostatin-receptor (SSTR)- based hybrid imaging with 68Ga-DOTATOC PET/CT. The patients included 171 with PanNETs, 305 with siNETs, and 166 with CUP NETs. The primary outcome was OS, defined as the time from date of initial NET diagnosis to death from any cause. Secondary outcomes included BM prevalence, entity-specific survival according to BM status, BM morphology and timing, and skeletal-related events.  Results: BM were detected in 238 patients (37.1%) and were most frequent in CUP NETs (42.8%), followed by PanNETs (36.3%) and siNETs (34.4%). Median OS in the overall cohort was 77 months (95% confidence interval [CI], 64–89) in patients with BM and 141 months (95% CI, 119–186) in metastatic patients without BM (log-rank p < 0.001). In CUP NETs, median OS was 30 months in patients with BM and 66 months in metastatic patients without BM (log-rank p = 0.021). In multivariable Cox regression adjusted for age, sex, tumor grade, functioning status, and tumor entity, BM remained associated with shorter OS (hazard ratio [HR], 1.45; 95% CI, 1.13–1.85; p = 0.0034). In an entity-stratified model BM remained associated with OS (HR, 1.43; 95% CI, 1.09–1.89; p = 0.011). In the CUP NET subgroup, the adjusted HR associated with BM was 1.83 (95% CI, 1.17–2.85; p = 0.008).  Conclusion: BM were common in patients with metastatic NETs and are particularly prevalent and clinically relevant in CUP NET.
SN  - 1664-2392
ER  -